Skip to content 
Diabetic Ketoacidosis
(DKA) Calculator
Instantly calculate DKA severity, anion gap, corrected sodium, effective osmolality, and bicarbonate deficit from lab values. Clinically aligned with 2026 ADA and Joint British Diabetes Societies (JBDS) guidelines — for education and clinical reference.
DKA Severity & Metabolic Calculator
Enter serum lab values — all key DKA metrics calculated instantly
DKA Severity Classification — 2026 ADA Criteria
The American Diabetes Association classifies DKA into three severity levels based on arterial pH, serum bicarbonate, urine/serum ketones, anion gap, and mental status. Each level demands a different care setting and management approach.
| Parameter | Mild DKA | Moderate DKA | Severe DKA | Normal Range |
|---|---|---|---|---|
| Plasma Glucose | >250 mg/dL | >250 mg/dL | >250 mg/dL | 70–99 mg/dL |
| Arterial pH | 7.25–7.30 | 7.00–<7.25 | <7.00 | 7.35–7.45 |
| Serum Bicarbonate | 15–18 mEq/L | 10–<15 mEq/L | <10 mEq/L | 22–26 mEq/L |
| Urine Ketones | Positive | Positive | Positive | Negative |
| Serum Ketones | Positive | Positive | Positive | Negative |
| Anion Gap | >10 mEq/L | >12 mEq/L | >14 mEq/L | 8–12 mEq/L |
| Mental Status | Alert | Alert/Drowsy | Stupor/Coma | Normal |
| Care Setting | ER / Stepdown | Hospital Ward | ICU Required | — |
DKA Calculation Formulas Used in This Calculator
Every metric our calculator produces is based on validated clinical formulas used by emergency physicians, intensivists, and endocrinologists. Here is the exact math behind each result.
Common Precipitating Causes of Diabetic Ketoacidosis
DKA does not occur spontaneously — it is almost always triggered by an identifiable precipitating factor. Identifying the cause is as critical as treating the metabolic crisis itself, because treating DKA without addressing the trigger leads to rapid recurrence.
Insulin Omission / Non-Adherence
The most common cause in known T1DM patients. Deliberate or accidental missed doses, insulin pump failure, or expired/denatured insulin can all precipitate DKA within hours.
Infection
Pneumonia, urinary tract infections, and COVID-19 are leading infectious triggers. Infection raises counter-regulatory hormones (cortisol, glucagon, epinephrine) that antagonize insulin and drive ketogenesis.
New-Onset Diabetes
Approximately 25–40% of new type 1 diabetes diagnoses present as DKA, with no prior insulin history. DKA may be the first clinical manifestation of previously undiagnosed T1DM.
Acute Myocardial Infarction
Cardiovascular events significantly elevate counter-regulatory hormones. DKA and MI can present simultaneously, and the hyperglycemia of DKA may be dismissed as stress hyperglycemia without ketone testing.
SGLT2 Inhibitors
A well-documented cause of euglycemic DKA — where blood glucose may be only mildly elevated (<250 mg/dL) but ketoacidosis is severe. Critical for clinicians to suspect in patients on dapagliflozin, empagliflozin, or canagliflozin.
Psychological Distress
Stress hormones from mental health crises, trauma, or psychological disorders can impair insulin sensitivity. DKA disproportionately affects younger patients with eating disorders and insulin-omission patterns.
Alcohol Use
Alcohol inhibits gluconeogenesis and stimulates ketogenesis. Alcoholic ketoacidosis can mimic DKA and may coexist with it, particularly in T1DM patients with alcohol use disorder.
Pancreatitis
Acute pancreatitis causes insulin deficiency and elevates glucagon, directly triggering the DKA metabolic cascade. The abdominal pain of pancreatitis can be confused with DKA’s own abdominal symptoms, delaying diagnosis.
DKA Treatment: The 5 Pillars of Management
DKA treatment follows a systematic approach. The order of interventions matters — particularly the requirement to begin IV fluids before insulin in most patients, and the critical potassium check before initiating insulin therapy.
- 1
Fluid Resuscitation — First and Aggressive
Begin with 1 liter of 0.9% normal saline over the first hour. Total fluid deficit in DKA is typically 3–6 liters. Subsequent fluids are guided by corrected serum sodium: if normal/high, use 0.45% saline; if low, continue 0.9% saline. Switch to 5% dextrose-containing saline when glucose falls to 200–250 mg/dL to prevent hypoglycemia while continuing insulin. Adequate fluid resuscitation reduces counter-regulatory hormone levels and partially corrects acidosis independent of insulin.
- 2
Potassium Replacement — Before Insulin if K⁺ <3.5 mEq/L
This is the most critical safety check in DKA management. Insulin drives potassium into cells, and without adequate serum potassium, starting insulin can precipitate life-threatening hypokalemia causing cardiac arrhythmia. If K⁺ <3.5 mEq/L: hold insulin, give IV potassium chloride (20–40 mEq/hr) until K⁺ ≥3.5 mEq/L, then start insulin. If K⁺ 3.5–5.5: start insulin and add 20–30 mEq KCl per liter of IV fluid. If K⁺ >5.5: start insulin, hold potassium, recheck in 2 hours.
- 3
Insulin Therapy — Fixed-Rate IV Infusion
The current 2026 JBDS guideline recommends a fixed-rate IV insulin infusion (FRIII) of 0.1 units/kg/hour as the standard of care, replacing the older variable-rate approach. Do not give an insulin bolus — there is no evidence of benefit and a risk of causing hypokalemia. For most adults without cardiovascular or renal compromise, continue the fixed rate regardless of glucose level — instead, add dextrose to the IV fluid when glucose <200–250 mg/dL to maintain the insulin rate until ketones resolve. Transition to subcutaneous insulin only after DKA resolution criteria are met and the patient is eating.
- 4
Electrolyte Monitoring and Replacement
Check serum electrolytes, glucose, and venous blood gas every 2–4 hours during active DKA treatment. Key targets: potassium 3.5–5.5 mEq/L throughout treatment; phosphate replacement if <1.0 mg/dL with symptomatic hypophosphatemia; magnesium replacement if <1.8 mg/dL. Avoid bicarbonate administration in most DKA — reserved only for pH <6.9 in severe cases, as bicarbonate therapy paradoxically worsens intracellular acidosis and hypokalemia.
- 5
Identify and Treat the Precipitating Cause
DKA will recur without addressing the trigger. Order blood cultures and urine culture if infection is suspected. Obtain ECG and troponin if MI is possible. Review medication adherence and insulin delivery device function in known diabetics. For new-onset DKA, initiate diabetes education before discharge. Patients with recurrent DKA may have psychosocial barriers requiring structured follow-up — recurrent DKA is associated with eating disorders, insulin omission, and inadequate access to diabetes supplies.
Understanding Diabetic Ketoacidosis — A Complete 2026 Reference
What Exactly Is Diabetic Ketoacidosis?
Diabetic ketoacidosis is a life-threatening acute metabolic emergency defined by the biochemical triad of hyperglycemia, ketonemia, and metabolic acidosis. It occurs when the body has insufficient insulin — either in absolute terms (type 1 diabetes, complete insulin cessation) or relative terms (type 2 diabetes with severe physiological stress) — to use glucose as cellular fuel. Without insulin, cells switch to fat metabolism, releasing fatty acids that the liver converts into ketone bodies: acetoacetate, beta-hydroxybutyrate, and acetone.
These ketone bodies are acidic. As they accumulate faster than the kidneys and lungs can clear them, blood pH drops, bicarbonate is consumed as a buffer, and the characteristic metabolic acidosis of DKA develops. Simultaneously, hyperglycemia creates an osmotic diuresis — the kidneys lose glucose in the urine, pulling water and electrolytes with it — causing profound dehydration and electrolyte depletion. The combined effects of acidosis, dehydration, and electrolyte disturbance are what make untreated DKA fatal, with historical mortality rates above 50% before modern treatment was established.
DKA in Type 2 Diabetes: The Underrecognized Presentation
While DKA is classically associated with type 1 diabetes, it occurs in type 2 diabetes far more frequently than most clinicians and patients recognize. Approximately 30–40% of DKA episodes in the United States now occur in people with type 2 diabetes. The proportion is even higher in specific populations: in African American and Hispanic patients, type 2 DKA accounts for the majority of cases — a phenomenon sometimes called “ketosis-prone type 2 diabetes” or the Flatbush diabetes variant.
A particularly important cause of type 2 DKA is SGLT2 inhibitor therapy. These medications (dapagliflozin, empagliflozin, canagliflozin, ertugliflozin) cause euglycemic DKA — a presentation where blood glucose may be only modestly elevated (180–250 mg/dL), yet severe ketoacidosis is present. Clinicians unfamiliar with this phenomenon may dismiss ketone testing because the glucose is “not that high,” leading to delayed diagnosis and potentially fatal outcomes. Any patient on SGLT2 inhibitors presenting with nausea, vomiting, fatigue, or dyspnea deserves serum ketone testing regardless of glucose level.
The Anion Gap: Your Most Important DKA Lab Value
The anion gap is the single most important laboratory calculation in DKA management. It reflects the accumulation of unmeasured anions — in DKA, primarily beta-hydroxybutyrate and acetoacetate — in the blood. The formula Na⁺ − (Cl⁻ + HCO₃⁻) captures the difference between the measured cation (sodium) and the measured anions (chloride and bicarbonate). In DKA, ketoacids fill this “gap,” elevating it well above the normal range of 8–12 mEq/L.
Critically, the anion gap is the most reliable indicator of DKA resolution. Resolution of DKA requires normalization of the anion gap to ≤12 mEq/L, not just correction of blood glucose. Glucose commonly normalizes within hours of insulin and fluid therapy, but ketoacidosis may persist for many more hours. A common clinical error is transitioning from IV to subcutaneous insulin when glucose reaches 200 mg/dL — without verifying that the anion gap has closed. This leads to rebound DKA within hours.
Euglycemic DKA: The Diagnosis You Can Miss
Euglycemic DKA (eu-DKA) represents a diagnostic trap for emergency physicians and internists unfamiliar with the pattern. Classic teaching defines DKA with glucose above 250 mg/dL — but this threshold fails in eu-DKA. Situations where glucose may be low or normal despite true DKA include: SGLT2 inhibitor use (most common), recent insulin administration before arrival, prolonged vomiting with poor oral intake, pregnancy, alcoholic ketoacidosis with concurrent DKA, and rarely, eating disorders with severe caloric restriction.
The clinical key is that eu-DKA has identical acidosis, identical ketone elevation, and identical anion gap elevation to classic DKA — only the glucose is misleadingly low. Treatment is the same, except glucose-containing fluids must be started from the outset (rather than later in the course) to prevent hypoglycemia during insulin infusion. Recognition of eu-DKA requires a high index of clinical suspicion — any patient with unexplained anion gap metabolic acidosis and positive ketones deserves DKA treatment regardless of the glucose level.
Comparing DKA to Hyperosmolar Hyperglycemic State (HHS)
DKA and hyperosmolar hyperglycemic state (HHS) represent two ends of the spectrum of hyperglycemic emergencies. They share hyperglycemia and dehydration but differ fundamentally in their biochemistry and typical patient populations. HHS occurs predominantly in older patients with type 2 diabetes, features extreme hyperglycemia (often 600–1200 mg/dL), minimal ketosis, and normal or near-normal pH — but severe osmolality elevation above 320 mOsm/kg and more profound volume depletion.
DKA typically has lower glucose levels, marked ketoacidosis, and occurs more often in type 1 diabetes or younger patients. The two conditions can overlap — “mixed DKA-HHS” — with both severe ketoacidosis and extreme hyperglycemia. Effective osmolality calculation (2 × Na + glucose/18 + BUN/2.8) helps differentiate: values above 320 mOsm/kg suggest significant HHS component requiring even more aggressive fluid resuscitation before insulin.
Why Potassium Monitoring Is a Matter of Life and Death in DKA
Potassium management is arguably the most life-critical aspect of DKA treatment. The paradox is this: at presentation, serum potassium is often normal or even elevated, despite total body potassium being severely depleted. Acidosis drives potassium out of cells into the bloodstream — so serum K⁺ looks adequate while intracellular stores are exhausted. When insulin is given, it rapidly drives potassium back into cells, and serum potassium plummets. Without proactive replacement, this shift can cause cardiac arrhythmias, including ventricular fibrillation and cardiac arrest, within hours of starting insulin.
This is not a theoretical risk. The 2026 JBDS guideline explicitly mandates checking serum potassium before initiating insulin in every DKA patient, and holding insulin if K⁺ is below 3.5 mEq/L. Every physician managing DKA must have this absolute rule memorized: potassium first, always, before insulin starts.
- Always use measured (not corrected) sodium when calculating the anion gap in DKA — using corrected sodium overestimates the gap
- The delta ratio helps identify mixed acid-base disorders superimposed on DKA — a ratio above 2 suggests concurrent metabolic alkalosis (from prolonged vomiting)
- Beta-hydroxybutyrate is the predominant ketone in DKA — urine ketone dipsticks (which primarily detect acetoacetate) can be misleadingly low at presentation and falsely appear to rise during treatment
- DKA can occur with pH above 7.3 if a concurrent metabolic alkalosis (from vomiting or diuretic use) masks the acidosis — elevated anion gap in this setting is the diagnostic clue
- Bicarbonate therapy is not recommended for DKA with pH above 6.9 — it causes paradoxical intracellular acidosis, worsens hypokalemia, and may impair oxygen delivery
- DKA is resolved when: glucose <200 mg/dL, serum HCO₃ ≥18 mEq/L, venous pH >7.30, AND anion gap ≤12 mEq/L — all four criteria must be met, not just glucose normalization
- Transition to subcutaneous insulin should overlap with IV insulin by 1–2 hours to prevent rebound ketoacidosis during the transition period
- Abdominal pain is a DKA symptom in up to 40% of cases — avoid attributing abdominal pain to a GI cause without first ruling out DKA with ketone testing
Frequently Asked Questions About DKA
Related Health Calculators on Click2Calc
These health and diabetes tools complement your DKA assessment — all available on Click2Calc.
